

# CVS | A Pharmacy Innovation Company



### **PBM Growth Strategy**

**Jon Roberts** 

Executive Vice President & President - CVS Caremark Pharmacy Services

## Agenda



Business update

Core growth opportunities

Unique enterprise initiatives




### Continued Positive Momentum In 2013 Selling Season



## 2013 Selling Season (\$ billions)

Gross new business 4.4

Retention rate 96%



#### \$24 billion of net-new business during the past three years


#### Notes:

- 1. PDP losses reflect impact of lost regions, net of benefit from new auto-assigns and open enrollment; excludes EGWPs.
- 2. Retention rate excludes impact of our net PDP losses.

### 2013 Selling Season: Winning Across All Segments



**Gross New Business:** \$4.4 billion













## Our Strategic Partnership With Aetna Is Gaining Share In The Marketplace In 2013



- Implementing more than one million new members
- Aetna CVS/pharmacy PDP offered in 29 Medicare regions
- Migration to CVS Caremark platform should be completed by the end of 2013
- Strategic programs an increasing part of Aetna's value proposition



### Pharmacy Advisor® Programs Are Gaining Rapid Adoption



#### **Condition Focus:**

- 2012 Diabetes
  - Hypertension
  - Dyslipidemia
  - Coronary Artery Disease
  - Congestive Heart Failure
- **2013** Asthma
  - COPD
  - Depression
  - Osteoporosis
  - Breast Cancer
- ~16 million lives enrolled in Pharmacy Advisor programs in 2013
- Expanding Pharmacy Advisor to Medicare




Members trust and value our pharmacists as part of their clinical team

## Client & Member Value Drive Continued Adoption Of Maintenance Choice®






(millions of members)



## Our Continuum Of Network Solutions Meet A Wide Range Of Client Needs ...








### ... And Enable Clients To Achieve Substantial Savings






~40% of new clients adopted a narrow network or Maintenance Choice

Note: Savings as a percent of gross retail spend. Source: CVS Caremark Retail Strategies.

## Streamlining Initiative On Track To Deliver Substantial Savings



## \$225 To \$275 Million In Estimated Annual Savings



- On track to deliver more than \$1 billion of cumulative savings from 2011 through 2015
- Benefits outweighed costs in 2012;
   should be more favorable in 2013
- Expect to hit full run rate of annual savings in 2014

## Streamlining Initiative Lays The Groundwork For Continuous Productivity Improvements



## Streamline Operations

• Two new automated mail pharmacies operational

### Rationalize Capacity

Completed workflow process redesign to improve efficiency

Continued facilities consolidation

Invest In Technology

 ~85% of business expected to be on destination platform by end of 2013

## Agenda



Business update

Core growth opportunities

Unique enterprise initiatives



## Well Positioned To Capitalize On Fastest-growing Market Segments



- 1 Medicare Part D
- Managed Medicaid
- 3 Specialty Pharmacy

## Medicare Is Quickly Emerging As A Major Payor For Prescription Drugs In America





- Traditional employer-sponsored coverage being replaced by Medicare Part D plans
  - Employer Group Waiver Plan (EGWP): employer sponsored, often with secondary benefits
  - Prescription Drug Plan (PDP): drug plans open to Medicare-eligibles
  - Medicare Advantage Prescription Drug (MA-PD): plans with medical and drug coverage

- Retirees below income thresholds eligible for low-income subsidies
  - Automatically assigned by Medicare, based on annual bid process

### Medicare Market Is Growing Rapidly And Consolidating







#### Notes:

- 1. Reflects enrollments recognized by CMS as of October 2012.
- 2. Excludes other PBMs.
- 3. Membership figures include Employer Group members reflecting CMS' standard enrollment reporting. Sources: U.S. Bureau of the Census, Medicare Trust Fund Report, 2012; CVS Caremark analysis.

### New SilverScript Choice Plan Attractive For Choosers





- Plan targeted at savvy senior shoppers
- Moderately priced, zero-deductible plan
- \$0 co-pay for tier one drugs in preferred network
- Innovative marketing solutions to drive enrollment


Enrolled more than 200,000 members in the 2013 plan year

## Medicaid Market Position Is Strong ... Tailoring Programs To Further Expand Our Leadership Position



### 2012 Managed Medicaid PBM Market

(estimated % of lives)



#### Member Engagement

Effective and direct interactions with Medicaid members to improve their care

#### Clinical And Cost Control

Products and services tailored to the needs of Medicaid plans and their members


#### **Operational Excellence**


Meeting client needs for a partner with deep Medicaid knowledge and competence at a low administrative cost

Sources: company reports; CVS Caremark analysis.

### Specialty Spend Expected To Double By 2016








By 2016, eight of the top ten drugs will be in specialty

Sources: CVS Caremark analysis; IMS Health; Buck Consultants; NHE; Credit Suisse; Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation, September 2011; 7 reasons why specialty drug dispensing will boom, Specialty Pharmacy Times, June 2012.

### Our Breadth Of Solutions Is Unmatched: A Continuum Of Options For Managing Specialty Trend





**Unit Cost** 

Optimize discounts, manage reimbursement and site of service

Utilization

Expand prior authorization and step edits

Drug Mix

**Product selection** 

Clients can save up to 12% to 16% of specialty spend

## Our Breadth Of Solutions Is Unmatched: Rheumatoid Arthritis Example



#### **Drugs In Pharmacy Benefit**

Specialty Guideline Management Preferred Drug Strategies Exclusive Pharmacy Network

#### **Drugs In Medical Benefit**

Benefit Alignment/ Optimization Site Of Care Management Medical Pharmacy/ Oncology Management

Has patient tried and failed methotrexate oral agent?


#### **Estimated Cost Per Month:**

- Methotrexate ~\$15
- Biologic average \$2,000 \$3,000



## Our Breadth Of Solutions Is Unmatched: Rheumatoid Arthritis Example





#### What is the preferred self-injectable?

Humira, Enbrel, Simponi, Cimzia, Orencia



## Our Breadth Of Solutions Is Unmatched: Rheumatoid Arthritis Example



#### **Drugs In Pharmacy Benefit**

Specialty Guideline Management Preferred Drug Strategies

Exclusive Pharmacy Network

#### **Drugs In Medical Benefit**

Benefit Alignment/ Optimization

Site Of Care Management Medical Pharmacy/ Oncology Management

Where is the most cost-effective site of treatment?

#### **Cost Per Treatment:**

• Hospital \$5,900

Home/Physician Office \$2,700 - \$2,900



## Agenda



Business update

Core growth opportunities

Unique enterprise initiatives



### Unique Enterprise Initiatives



Create greater health care value

Serve customers in new ways

Optimize enterprise assets

**Unlock Adherence** 

**Transform Primary Care** 

**Expand Role In Specialty** 

**Differentiate For Providers** 

Partner With Health Plans

**Integrated Digital Offering** 

Integrated Specialty

## Integrated Specialty: Uniquely Positioned To Offer Specialty Patients Pharmacy Of Choice



## Intake From Anywhere



7,400 Retail Stores



Our Specialty Mail Pharmacies

## Integrated Services Provided Centrally




Expert
On-boarding
And
Processing



Consistent, High-quality Clinical Services

## Convenient Delivery



In-store Pick-up



**Home Delivery** 


Unmatched access, convenience and clinical quality

Note: Prescriptions enter through complete range of current channels—mail, digital, phone, voicemail, fax, walk-in, other pharmacy, and PBM, among others.

### Initial Pilot Results: New Therapy Starts Up 112% Over Four Months








#### Notes:

- 1. Non-Pilot Control based on data from 63 stores which was normalized to match the number of stores used for each test and indexed to Pre-Test Fills.
- 2. 3rd and 4th months for pilot only include data from mini-test.
- 3. Analysis excludes any patient and NDC combination which shows Rx Fill Nbr 0 but has been presented within pilot market during FY12.

### Strong Specialty Growth Expected To Continue





### Unique Enterprise Initiatives



Create greater health care value

Serve customers in new ways

Optimize enterprise assets

**Unlock Adherence** 

**Transform Primary Care** 

**Expand Role In Specialty** 

**Differentiate For Providers** 

Partner With Health Plans

**Integrated Digital Offering** 

MinuteClinic Co-pay Reduction

## MinuteClinic Co-pay Reduction With Marriott: Program Yielding Promising Results



Member out-of-pocket cost



Visits vs. baseline



First-time users

67%



### Uniquely Positioned For Growth



- Continue to achieve profitable net-new business
- Leverage unique model to create truly distinctive client and member value
- Continue progress in driving clinical outcomes
- Build on leadership position in Specialty,
   Medicare and Medicaid

 Establish a culture of continuous productivity improvement

